OncLive® On Air

Dr Mian discussed why frailty should be understood as a dynamic, evolving clinical state rather than a fixed baseline characteristic

In today’s episode, we had the pleasure of speaking with Sikander Ailawadhi, MD, and Beth Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO, about the potential clinical implications of the phase 3 IRAKLIA (NCT05405166) and phase 2 IZALCO (NCT05704049) studies, which investigated the use of isatuximab-irfc (Sarclisa) administered via an on-body delivery system in patients with relapsed/refractory multiple myeloma. Ailawadhi is a consultant in the Division of Hematology/Oncology in the Department of Internal Medicine, a consultant in the Department of Cancer Biology, and a professor of medicine at Mayo Clinic in Jacksonville, Florida. Faiman is a nurse practitioner in the Multiple Myeloma Program at Cleveland Clinic in Ohio.

In our exclusive interview, Ailawadhi and Faiman discussed the rationale for efforts to bring isatuximab on-body injectors into the clinic, key patient-reported outcome findings from these studies, and how these findings may one day influence therapy administration across the broader multiple myeloma treatment paradigm.

Closing the Gap: Understanding Gender Disparities in Bladder Cancer Care, hosted by Martha K. Terris, MD, FACS, is a limited series spotlighting unique considerations for bladder cancer diagnosis and treatment among women. Dr Terris is department chair and a professor in the Department of Urology, the Witherington Distinguished Chair in Urology, and co-director of the Cancer Center at the Medical College of Georgia at Augusta University. 

In part 1 of this 3-part series, Dr Terris discussed the prevalence of bladder cancer in women, as well as reasons for diagnostic disparities that contribute to poor treatment outcomes. She noted that this disease is often diagnosed at later stages in women than in men, often resulting in diagnoses of more advanced disease and translating to poorer outcomes. She added that although female patients represent a minority of those with urothelial carcinoma, retrospective data indicate that women tend to be diagnosed at later stages and consequently experience worse survival rates, regardless of the disease stage.

Dr Terris identified several theories explaining why this diagnosis delay occurs. One possible reason is patient-related: women may be less likely than men to consult a physician when they notice blood in their urine because they may be conditioned to dismiss blood if they experience menstrual bleeding. However, physician behavior and bias also contribute to diagnostic disparities, Terris said. Women with suspected hematuria typically receive fewer imaging tests, she continued. Additionally, physicians may be biased, attributing hematuria to uterine bleeding, menstruation, or other benign causes. 

Overall, Terris emphasized that early detection is key. If there is any suspicion of a malignancy, patients should be referred directly to a urologist, she stated. Urologists should be willing to work up cases that might ultimately be recurrent urinary tract infections or radiation cystitis to avoid undiagnosed cases of bladder cancer in women, she concluded.

At the 2025 ESMO Congress, leading oncologists reflected on data expected to redefine practice across breast, genitourinary, and gynecologic malignancies.

In today’s episode, we had the pleasure of speaking with Neal Shore, MD, FACS, about the use of androgen deprivation therapy (ADT) in prostate cancer management. Dr Shore is medical director of the Carolina Urologic Research Center in Myrtle Beach, South Carolina.

In our exclusive interview, Dr Shore discussed guidelines for incorporating ADT into prostate cancer clinical practice, toxicities and quality-of-life complications associated with this class of agents that health care providers should be aware of and try to mitigate, and the importance of shared decision-making between members of the multidisciplinary team, as well as patients.

In this episode, Ziad Hanhan, MD, hosted a discussion about lung cancer diagnosis, surgical management, and evolving treatment paradigms. Dr Hanhan is a thoracic surgeon at Hackensack Meridian Health, chairman of Surgery at Bayshore Medical Center in Holmdel, New Jersey, and chief of Thoracic Surgery at Riverview Medical Center in Red Bank, New Jersey. He was joined by:

Drs Hanhan, Bauer, and NeMoyer discussed current standards and future directions in thoracic oncology, emphasizing multidisciplinary collaboration and technological innovation. The conversation opened with an overview of lung cancer epidemiology, and the experts noted that this disease remains the leading cause of cancer-related mortality in both men and women. They explained that approximately 90% of lung cancer cases are attributable to tobacco use, making cessation a key preventive measure. They also emphasized that early detection through low-dose CT screening improves outcomes when the disease is identified at an early stage. However, despite these advances, they stated that most lung cancer cases in the United States continue to be diagnosed at stage III or IV, underscoring the need for improved screening adherence.

They expanded on current lung cancer screening guidelines and noted that lung cancer often presents with nonspecific symptoms, such as chronic cough or hemoptysis, and that many cases are discovered incidentally on imaging. The surgeons also discussed diagnostic strategies for pulmonary nodules and emphasized a patient-tailored approach that balances diagnostic yield with procedural risk. They also acknowledged that emerging modalities, such as liquid biopsy and breath-based DNA detection, are promising but still investigational.

They underscored that frailty assessment remains integral to surgical candidacy determination, with both clinical evaluation and pulmonary function testing guiding decision-making. The team also highlighted the role of multidisciplinary tumor boards in integrating surgical, medical, and radiation oncology perspectives. For early-stage disease, surgery remains the standard, whereas patients with stage III disease typically receive neoadjuvant therapy incorporating immuno-oncology agents. The group also discussed expanding surgical indications in select stage IV cases, reflecting improved survival associated with immunotherapy.

Dr Mehta discussed practice-changing urothelial carcinoma data that have been presented throughout 2024 and 2025, the clinical utility of enfortumab vedotin plus pembrolizumab for select patients with advanced or metastatic urothelial cancer, and differing treatment approaches for patients with lymph node–only vs distant metastases.

In today’s episode, we had the pleasure of speaking with Armeen Mahvash, MD, about the FDA approval of SIR-Spheres Y-90 resin microspheres for the treatment of patients with unresectable hepatocellular carcinoma. Dr Mahvash is a professor in the Department of Interventional Radiology in the Division of Diagnostic Imaging at The University of Texas MD Anderson Cancer Center in Houston, as well as an assistant professor in the Department of Diagnostic and Interventional Imaging at The University of Texas Medical School at Houston.

In our exclusive interview, Dr Mahvash discussed the significance of this approval, key clinical findings that led to the approval, and how multidisciplinary collaboration is crucial for implementing radioembolization in practice.

In today’s episode, we had the pleasure of speaking with Vishal A. Patel, MD, FAAD, FACMS, about the FDA approval of adjuvant cemiplimab-rwlc (Libtayo) for the treatment of patients with high-risk cutaneous squamous cell carcinoma (CSCC). Dr Patel is an associate professor of dermatology at the GW School of Medicine & Health Sciences, as well as the director of the Cutaneous Oncology Program at the GW Cancer Center in Washington, DC.

In our exclusive interview, Dr Patel discussed the clinical relevance of this approval, key details about the pivotal phase 3 C-POST trial (NCT03969004), and the safety profile of cemiplimab in patients with CSCC.

In this podcast, experts Tina Cascone, MD, PhD; Christina Baik, MD, MPH; and David Planchard, MD, PhD discuss data-driven treatment for EGFR-mutant non-small cell lung cancer.